Skip to main content

Glaxo Wellcome plc, and SmithKline Beecham plc, In the Matter of

Tags:

Last Updated

January 30, 2001

In the Matter of Glaxo Wellcome plc, and SmithKline Beecham plc

FTC Matter/File Number

0010088

Docket Number

C-3990

Enforcement Type

Part 2 Consents

Case Summary

Under terms of a final consent order settling charges stemming from the merger of SmithKline and Glaxo Wellcome plc, the parties agreed to divest pharmaceutical products in six markets: antiemetics; the antibiotic, ceftazidime; oral and intravenous antiviral drugs for the treatment of herpes; topical antiviral drugs for the treatment of genital herpes; and over-the-counter H-2 blocker acid relief products.

Case Timeline

January 30, 2001

Decision and Order (110.79 KB)

Trust Agreement (22.69 KB)

Attachment 1 (Hoffmann-La Roche) (13.88 KB)

Attachment 2 (Novartis) (13.92 KB)

Attachment 3 (Abbott) (13.78 KB)

Order to Maintain Assets (13.37 KB)

Complaint (17.45 KB)

Closing Letter As to One Part of the Investigation (3.55 KB)

PRESS RELEASE: Announced Actions for January 30, 2001

December 18, 2000

Agreement Containing Consent Orders (10.61 KB)

Decision and Order (4.97 MB)

Order to Maintain Assets (13.37 KB)

Complaint (17.45 KB)

Analysis of Proposed Consent Order to Aid Public Comment (29.86 KB)

Trust Agreement (22.69 KB)

Attachment 1 (Hoffmann-La Roche) (13.88 KB)

Attachment 2 (Novartis) (13.92 KB)

Attachment 3 (Abbott) (13.78 KB)

PRESS RELEASE: Resolving Competitive Concerns, FTC Agreement Clears $182 Billion Merger of SmithKline Beecham And Glaxo Wellcome